MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
According to MaxCyte, Inc.'s latest financial reports the company's current revenue (TTM) is $41.29 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
---|---|---|---|---|---|
2023 | $41.29 M | $36.55 M | $-44,128,000 | $-37,923,000 | $-37,923,000 |
2022 | $44.26 M | $39.16 M | $-20,872,900 | $-23,570,800 | $-19,781,100 |
2021 | $33.89 M | $30.25 M | $-16,764,700 | $-19,082,200 | $-20,126,600 |
2020 | $26.17 M | $23.4 M | $-9,943,100 | $-11,816,400 | $-12,642,000 |
2019 | $21.62 M | $19.12 M | $-11,600,400 | $-12,895,000 | $-13,576,100 |
2018 | $16.67 M | $14.83 M | $-7,910,600 | $-8,869,200 | $-8,869,200 |
2017 | $13.99 M | $12.53 M | $-9,148,800 | $-9,917,000 | $-9,917,000 |
2016 | $12.27 M | $10.96 M | $-2,602,000 | $-3,345,500 | $-3,345,500 |
2015 | $9.29 M | $8.26 M | $-647,800 | $-1,445,500 | $-1,445,500 |
2014 | $7.16 M | $6.21 M | $-1,183,700 | $-1,837,000 | $-1,837,000 |
2013 | $6.81 M | $6 M | $-688,300 | $-958,200 | $-958,200 |
2012 | $5.06 M | $4.23 M | $-1,811,500 | $-1,988,400 | $-1,988,400 |